Alexandria Real Estate Equities Inc
F:A6W
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alexandria Real Estate Equities Inc
F:A6W
|
US |
|
Bank Jago Tbk PT
IDX:ARTO
|
ID |
|
C
|
CVS Health Corp
XMUN:CVS
|
US |
|
F
|
Federal National Mortgage Association
SWB:FNM
|
US |
|
R
|
RWE AG
F:RWE
|
DE |
|
United Plantations Bhd
OTC:UPBMF
|
MY |
|
T
|
Toyota Motor Corp
XBER:TOM
|
JP |
|
Consti Oyj
LSE:0RD9
|
FI |
|
Qinghai Salt Lake Industry Co Ltd
SZSE:000792
|
CN |
Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities is a real estate company that owns, develops, and manages specialized office and lab buildings for the life sciences industry. Its properties are designed for companies that need space for research, laboratory work, and office operations, especially in markets with dense clusters of biotech, pharmaceutical, and academic activity. Its main customers are drug makers, biotech startups, medical research firms, and other science-focused tenants. Alexandria earns most of its money by leasing space to these tenants and, in some cases, by developing new properties and upgrading existing ones to fit the technical needs of lab users. Because these buildings require specialized design, power, ventilation, and safety features, they are harder to replace than ordinary office space. The company sits between the real estate market and the life sciences industry. Instead of building generic offices, it focuses on campuses and buildings that support research work and long tenant relationships. That makes its business model different from a standard office landlord: it depends on the demand for scientific research space, and its properties are tied to the growth of companies that need a place to discover, test, and develop new drugs and technologies.
Alexandria Real Estate Equities is a real estate company that owns, develops, and manages specialized office and lab buildings for the life sciences industry. Its properties are designed for companies that need space for research, laboratory work, and office operations, especially in markets with dense clusters of biotech, pharmaceutical, and academic activity.
Its main customers are drug makers, biotech startups, medical research firms, and other science-focused tenants. Alexandria earns most of its money by leasing space to these tenants and, in some cases, by developing new properties and upgrading existing ones to fit the technical needs of lab users. Because these buildings require specialized design, power, ventilation, and safety features, they are harder to replace than ordinary office space.
The company sits between the real estate market and the life sciences industry. Instead of building generic offices, it focuses on campuses and buildings that support research work and long tenant relationships. That makes its business model different from a standard office landlord: it depends on the demand for scientific research space, and its properties are tied to the growth of companies that need a place to discover, test, and develop new drugs and technologies.
FFO: Alexandria reported first-quarter adjusted FFO of $1.73 per share and reaffirmed its full-year 2026 midpoint of $6.40, while tightening the range.
Leasing: Leasing was weak at 647,000 square feet, with no public biotech leases in the quarter, but management expects a pickup in the second quarter to around 900,000 square feet based on current activity.
Occupancy: Occupancy fell to 87.7% as expected lease expirations rolled vacant, and year-end occupancy guidance was cut to 87% from 88.5%.
Demand Mix: Management said public biotech remains the softest part of the market, while private biotech is still raising capital more carefully and interest is increasing in alternative advanced-technology uses.
Capital Plan: The company kept its $2.9 billion disposition and partial-interest sales midpoint, but shifted the mix toward assets with more stable occupancy and is considering more joint ventures.
AI Impact: Management said AI is not yet changing real estate demand in a material way; it may improve efficiency, but it does not replace physical lab experimentation.
